HealthDay News — The demand for psilocybin-assisted therapy (PSIL-AT) for major depressive disorder (MDD) and treatment-resistant depression (TRD) varies from 24 to 62 percent depending on the ...

Reduced risk for Alzheimer disease, vascular dementia, and Parkinson disease seen with SGLT2i use in type 2 diabetes.

Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...

The Food and Drug Administration (FDA) has approved Fasenra ® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable ...